How to Inject Thymosin Alpha-1: Sites, Syringes and Steps
Where to inject Thymosin Alpha-1, which syringe to use, how to read units and the hygiene steps that prevent infection.
Injection sites
Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.
- Belly: at least 2 inches (5 cm) away from the navel.
- Front and outer thighs.
- Back of the upper arms, if someone else can reach it.
- Rotate sites each time and avoid skin that is bruised, scarred or irritated.
Syringe and needle
U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for Thymosin Alpha-1 in studies: not reported in study abstracts (PubMed search, 11 Oct 2026).
How to read an insulin syringeStep by step
- 1Wash your handsUse soap and water, and work on a clean surface.
- 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
- 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
- 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
- 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
- 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
Routes and schedules the trials used
The TESTS sepsis trial gave subcutaneous thymosin alpha 1 or placebo every 12 hours, for up to a week unless stopped sooner.[14]
The severe pancreatitis pilot injected 3.2 mg twice per day for 7 days.[15]
The hepatocellular carcinoma trial gave 1.6 mg subcutaneously 5 times weekly for 24 weeks alongside chemoembolization.[16]
A hepatitis C combination study gave 1.6 mg subcutaneously twice a week for 52 weeks alongside interferon alpha 2a.[17]
The hepatitis B trial against interferon gave 900 microg/m2 of body surface area twice weekly for 6 months.[18]
What the trials said about the injection site
In the hepatitis B and hepatitis C trials, local discomfort at the injection sites was the only side effect named.[19]
In healthy volunteers, thymosin alpha 1 was well absorbed after subcutaneous injection, with a mean time to peak of 1 to 2 hours.[20]
No approved label to quote
Drugs@FDA returned no matches for thymalfasin, so there is no FDA label with injection-site, rotation or storage steps to quote here.[21]
Common questions
Where do you inject Thymosin Alpha-1?
Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.
What syringe is used for Thymosin Alpha-1?
Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.
How often is Thymosin Alpha-1 injected?
The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.
Where is thymosin alpha 1 injected in studies?
The trial abstracts describe subcutaneous injection and give schedules but do not name body sites.[14]
How often was thymosin alpha 1 injected in trials?
Schedules in the cached trials ranged from twice daily to twice weekly, depending on the condition studied.[15]
More on Thymosin Alpha-1
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) (956 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (randomized[tiab] OR "clinical trial"[pt] OR "meta-analysis"[pt]) (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (sepsis[tiab] OR septic[tiab]) (51 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (COVID-19[tiab] OR SARS-CoV-2[tiab]) (44 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (hepatitis[tiab]) (131 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND ("meta-analysis"[pt] OR "systematic review"[pt]) (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (allerg*[tiab] OR asthma[tiab] OR rhinitis[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (143 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 12PubMed search: ("thymosin alpha 1"[tiab] OR "thymosin alpha1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab] OR Talpha1[tiab]) AND (randomized[tiab] OR "clinical trial"[pt] OR "phase II"[tiab] OR "phase I"[tiab]) AND ("adverse events"[tiab] OR "adverse effects"[tiab] OR toxicity[tiab] OR "injection site"[tiab] OR tolerated[tiab]) (37 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 13PubMed search: ("thymosin alpha 1"[tiab] OR thymalfasin[tiab] OR Zadaxin[tiab]) AND ("injection site"[tiab] OR "local discomfort"[tiab] OR "side effects"[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 14The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025PMID 39814420Accessed 2 Oct 2026
- 15Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study.Inflammation · 2011PMID 20549321Accessed 2 Oct 2026
- 16A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.Hepatology international · 2009PMID 19669251Accessed 2 Oct 2026
- 17The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results.Journal of the Medical Association of Thailand = Chotmaihet thangphaet · 2001PMID 11529376Accessed 11 Oct 2026
- 18A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.Hepatology (Baltimore, Md.) · 1996PMID 8855175Accessed 11 Oct 2026
- 19A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.Liver · 1996PMID 8873009Accessed 11 Oct 2026
- 20Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.International journal of clinical pharmacology and therapeutics · 1999PMID 10027483Accessed 2 Oct 2026
- 21Drugs@FDA (openFDA) search: active ingredient "thymalfasin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.